2 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
of products sold and the launch of new products. Research and development (R&D) expense was $28.5
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
annualized cost savings of more than $25 million.Expected SG&A and R&D expenses for 2024 reduced from $301.5
- Prev
- 1
- Next